This revised standing order is issued pursuant to P.L.2021, c.152 ("Act"), which provides that the Commissioner of Health, or, if the commissioner is not a duly licensed physician, the Deputy Commissioner for Public Health Services, shall issue a standing order authorizing a recipient in possession of an opioid antidote “to distribute the opioid antidote, without fee, to any other person whom the recipient reasonably believes to be at risk of experiencing an opioid overdose or whom the recipient reasonably believes will be in a position to administer the opioid antidote to a person experiencing an opioid overdose.”

The purpose of this standing order is to make opioid antidotes as easily accessible and as widely available as possible in order to provide treatment to people experiencing a suspected overdose. Nothing in this standing order shall be construed to restrict in any way the ability of any individual or entity to be dispensed an opioid antidote.

The Act defines the following terms:

- "Opioid antidote" as “any drug, regardless of dosage amount or method of administration which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. ‘Opioid antidote’ includes, but is not limited to naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods. “

- “Drug overdose” means “an acute condition including, but not limited to, physical illness, coma, mania, hysteria, diminished consciousness, respiratory depression, or death resulting from the consumption or use of a controlled dangerous substance or another substance with which a controlled dangerous substance was combined and that a layperson would reasonably believe to require medical assistance.”
“Recipient” means “any individual who or entity that is prescribed or dispensed an opioid antidote” in accordance with N.J.S.A. 24:6J-4 or N.J.S.A. 45:14-67.2 including, but not be limited to, “private citizens, emergency medical responders, emergency medical response entities, law enforcement officers, law enforcement agencies, recognized places of public access, employees and volunteers providing services at, through, or on behalf of a recognized place of public access, public and nonpublic schools, school nurses and other staff at a public or nonpublic school, sterile syringe access programs, and staff and employees of a sterile syringe access program. The term ‘recipient’ shall not include a prescriber or a licensed pharmacist acting within a professional capacity.”

I. AUTHORIZATION

A. This standing order may be used by any recipient in possession of an opioid antidote to distribute an opioid antidote, without fee, to any other person whom the recipient reasonably believes to be at risk of experiencing an opioid overdose or whom the recipient reasonably believes will be in a position to administer the opioid antidote to a person experiencing an opioid overdose. A recipient distributing an opioid antidote to another person pursuant to this paragraph shall make reasonable efforts to furnish the person with the overdose prevention information set forth in Section II below.

B. A recipient may mail one or more opioid antidotes to New Jersey residents in any manner not otherwise prohibited by or inconsistent with State or federal law or regulation.

II. INFORMATION

A recipient distributing an opioid antidote to another person pursuant to this standing order shall make reasonable efforts to furnish the person with the following overdose prevention information:

A. Information on opioid overdose prevention and recognition;
B. Instructions on how to perform rescue breathing and resuscitation;
C. Information on dosage and instructions regarding administration in conjunction with the packaging insert included with the opioid antidote;
D. Information regarding circumstances which warrant calling 911 for assistance with an opioid overdose;
E. Instructions regarding appropriate care of an overdose victim after administration of an opioid antidote; and
F. Information on contraindications and precautions.
III. ADDITIONAL INFORMATION

In addition to the information set forth in Section II above, the recipient distributing the opioid antidote may also direct the individual receiving the opioid antidote to the following website for additional information regarding opioid overdose prevention and opioid antidotes: https://nj.gov/humanservices/dmhas/initiatives/naloxone.html.

IV. EXPIRATION AND REVIEW

This revised standing order supersedes the standing orders issued on August 31, 2021 and August 24, 2022.

This revised standing order shall not expire unless and until all forms of opioid antidotes have been approved as over-the-counter medications or until otherwise withdrawn in writing by the Department of Health. This revised standing order will be reviewed periodically and updated as relevant developments in the law or science about opioid antidote administration occur.

New Jersey Department of Health
Issuing Official

Margaret C Fisher
Margaret Fisher, MD
Acting Deputy Commissioner
Public Health Services
New Jersey Department of Health
NPI Number: 1932165701
NJ License Number: 25MA07136300

9/7/22
Date